论文部分内容阅读
目的探讨吡格列酮联合厄贝沙坦及阿托伐他汀治疗早期糖尿病肾病的临床疗效。方法选取2011—2014年魏县人民医院收治的早期糖尿病肾病患者114例,随机分为对照组55例和观察组59例。两组患者均给予胰岛素及吡格列酮、厄贝沙坦治疗,观察组另加用阿托伐他汀治疗。观察两组患者治疗前后的血脂及肾功能变化情况。结果治疗前两组患者的血脂及肾功能比较,差异无统计学意义(P>0.05);治疗后观察组患者的总胆固醇、三酰甘油、低密度脂蛋白、血肌酐、血尿素氮水平及尿微量清蛋白、尿微量清蛋白排泄量均低于对照组(P<0.05),而两组高密度脂蛋白水平比较,差异无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论吡格列酮联合厄贝沙坦及阿托伐他汀治疗早期糖尿病肾病的临床疗效确切,可有效改善患者血脂代谢及肾功能。
Objective To investigate the clinical efficacy of pioglitazone combined with irbesartan and atorvastatin in the treatment of early diabetic nephropathy. Methods 114 patients with early diabetic nephropathy admitted from Weixian People’s Hospital from 2011 to 2014 were randomly divided into control group (55 cases) and observation group (59 cases). Both groups were given insulin and pioglitazone, irbesartan treatment, the observation group plus atorvastatin treatment. The changes of blood lipid and renal function in two groups before and after treatment were observed. Results There was no significant difference in serum lipids and renal function between the two groups before treatment (P> 0.05). After treatment, total cholesterol, triglyceride, LDL, serum creatinine, blood urea nitrogen Urinary albumin and urinary albumin excretion were lower than those of the control group (P <0.05). There was no significant difference between the two groups in the level of HDL (P> 0.05). The incidence of adverse reactions in the two groups, the difference was not statistically significant (P> 0.05). Conclusions Pioglitazone combined with irbesartan and atorvastatin has definite curative effect on early diabetic nephropathy and can effectively improve the blood lipid metabolism and renal function.